National Geographic : 2019 Jun
IT’S TRU. Learn more at keytruda.com Dr. Goetz Kloecker is a practicing oncologist and has been compensated for his time. KEYTRUDA is a prescription medicine used to treat a kind of lung cancer called NSCLC. KEYTRUDA may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene. EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase. IMPORTANT SAFETY INFORMATION KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended. Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse: • Lung problems (pneumonitis). Symptoms of pneumonitis may include shortness of breath, chest pain, or new or worse cough. • Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness. • Liver problems (hepatitis). Signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, feeling less hungry than usual, or bleeding or bruising more easily than normal. • Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include rapid heartbeat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache. • Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include change in the amount or color of your urine. • Skin problems. Signs of skin problems may include rash, itching, blisters, peeling or skin sores, or painful sores or ulcers in your mouth or in your nose, throat, or genital area. • Problems in other organs. Signs and symptoms of these problems may include changes in eyesight; severe or persistent muscle or joint pains; severe muscle weakness; low red blood cells (anemia); swollen lymph nodes, rash or tender lumps on skin, cough, shortness of breath, vision changes, or eye pain (sarcoidosis); confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures (encephalitis); and shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis). • Infusion (IV) reactions that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, shortness of breath or wheezing, itching or rash, flushing, dizziness, fever, or feeling like passing out. KEYTRUDA immunotherapy + chemotherapy (pemetrexed and a platinum) for advanced nonsquamous, non–small cell lung cancer that does not have an abnormal EGFR or ALK gene. Important Safety Information is continued on the next page. Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. US-LAM-00131 03/19 keytruda.com IMPORTANT SAFETY INFORMATION (continued) • Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection if they are treated with KEYTRUDA. • Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain, and diarrhea. Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects. Before you receive KEYTRUDA, tell your doctor if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or plan to have or have had a bone marrow (stem cell) transplant that used donor stem cells (allogeneic); have lung or breathing problems; have liver problems; or have any other medical problems. If you are pregnant or plan to become pregnant, tell your doctor. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, your doctor will give you a pregnancy test before you start treatment. Use effective birth control during treatment and for at least 4 months after the final dose of KEYTRUDA. Tell your doctor right away if you think you may be pregnant or you become pregnant during treatment with KEYTRUDA. If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Common side effects of KEYTRUDA when given with certain chemotherapy medicines include: feeling tired or weak, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, trouble breathing, fever, hair loss, and inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs. These are not all the possible side effects of KEYTRUDA. Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist. Please read the adjacent Important Information About KEYTRUDA and discuss it with your oncologist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Having trouble paying for your Merck medicine? Merck may be able to help. www.merckhelps.com “TREATMENTS LIKE KEYTRUDA WITH CHEMOTHERAPY REALLY BREAK THROUGH BARRIERS WE HAD NOT LONG AGO.” —DR. GOETZ KLOECKER KEYTRUDA will not work for everyone. Results may vary. WHEN TREATED WITH A COMBINATION OF KEYTRUDA AND CHEMOTHERAPY: A clinical trial compared patients with advanced nonsquamous, non–small cell lung cancer (NSCLC) who received KEYTRUDA in combination with chemotherapy (410 patients) with those who received chemotherapy alone (206 patients). Patients in the trial did not have an abnormal EGFR or ALK gene and had no previous drug treatment. 69% of patients taking KEYTRUDA with chemotherapy were alive compared with 48% taking chemotherapy alone. MORE PATIENTS LIVED LONGER 48% of patients taking KEYTRUDA with chemotherapy saw their tumors shrink compared with 19% taking chemotherapy alone. MORE PATIENTS SAW THEIR TUMORS SHRINK The median duration of response to treatment was 11.2 months for patients treated with a combination of KEYTRUDA and chemotherapy compared with 7.8 months for those on chemotherapy alone. The immunotherapy with the most FDA-approved uses for advanced lung cancer Half of the patients receiving KEYTRUDA with chemotherapy were alive without their cancer spreading, growing, or getting worse at 8.8 months compared with 4.9 months for patients receiving chemotherapy alone. Cancer did not progress in 40% of patients receiving KEYTRUDA with chemotherapy compared with 19% of patients receiving chemotherapy alone.